Save 10% off all print and digital GUIDELINES Pocket Guides for a limited time!   Use code SUMMERSAVINGS

Differentiated Thyroid Cancer GUIDELINES Pocket Guide

Approved By

American Thyroid Association

Digital $8.99 Add to Cart
Print $13.95 Add to Cart
Free Sample

The digital version of the ATA Differentiated Thyroid Cancer GUIDELINES contains all the same great information found in the pocket guide, and can be accessed on mobile devices and online:

  • For a single low price: $8.99
  • Includes automatic updates on drugs and indications
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on mobile apps accessible without internet connection
  • Including off-line access to thousands of guideline summaries and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

Click Here for more information on Thyroid Cancer and Thyroid Related Disorders.

The Differentiated Thyroid Cancer GUIDELINES Pocket Guide is based on the latest guidelines of the American Thyroid Association and was developed with their collaboration. This practical quick-reference tool contains  key points,  101 detailed, evidence-graded recommendations for managing recurrent or persistent differentiated thyroid cancer, four management algorithms, and tables dealing with disease classification, treatment response, risk.

  • Spiral Bound
  • 32 Pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Key Points 
  • Graded Treatment Recommendations 
  • Tables 
    • Ultrasound Features of Lymph Nodes Predictive of Malignant Involvement 
    • AJCC 7th edition/TNM Classification System for Differentiated Thyroid Carcinoma
    • Pre-operative Factors Which May Be Associated With Laryngeal Nerve Dysfunction
    • Best Response to Therapy
    • Clinical Implications of Response To Therapy Re-Classification in Differentiated Thyroid Cancer Patients Treated With Total Thyroidectomy and RAI Remnant Ablation
    •  Characteristics According to the ATA Risk Stratification System and AJCC/TNM Staging System That May Affect Post-operative RAI Decision-Making
    • Response to Therapy Re-Classification
    • TSH Targets for Long-term Thyroid Hormone Therapy
    •  Factors to Review When Considering Kinase Inhibitor Therapy
    • Potential Toxicities and Recommended Screening or Surveillance Monitoring Approaches in Patients Started on Kinase Inhibitor Therapy
  • Algorithms 

The ATA is the leading organization devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health. To learn more, visit -

Contact Us
106 Commerce Street Suite 105
Lake Mary, Florida 32746
(407) 878-7606

  • This field is for validation purposes and should be left unchanged.

To get started, log in or create your free account Create Account